Teresa M Wozniak1. 1. Centre for Research Excellence - Reducing Healthcare-Associated Infections, Australian Centre for Health Services Innovation, Queensland University of Technology, Queensland, Australia. Electronic address: wozniakt@qut.edu.au.
Abstract
BACKGROUND: To gain a better understanding of clinical practice for the treatment of common drug-resistant infections. METHODS: A web-based anonymous survey was developed to gain a better understanding of clinical practice of patients infected with drug-resistant bloodstream infections (BSI). The survey instrument was a questionnaire requesting doctors to provide their opinion on the most likely choice of an antibiotic, dose and route of administration for patients infected with a drug-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa or Enterococcus faecium. RESULTS: All of the survey participants (n = 28) were hospital-based doctors. Choice of therapy for drug-resistant E. coli and K. pneumoniae was uniform across survey participants. However, optimal treatment of ceftazidime-resistant P. aeruginosa and VRE was less clear. CONCLUSION: The survey adds to the limited body of evidence in this clinical area and can be a useful tool for health economists in determining the additional cost of treating patients with drug-resistant infections.
BACKGROUND: To gain a better understanding of clinical practice for the treatment of common drug-resistant infections. METHODS: A web-based anonymous survey was developed to gain a better understanding of clinical practice of patients infected with drug-resistant bloodstream infections (BSI). The survey instrument was a questionnaire requesting doctors to provide their opinion on the most likely choice of an antibiotic, dose and route of administration for patients infected with a drug-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa or Enterococcus faecium. RESULTS: All of the survey participants (n = 28) were hospital-based doctors. Choice of therapy for drug-resistant E. coli and K. pneumoniae was uniform across survey participants. However, optimal treatment of ceftazidime-resistant P. aeruginosa and VRE was less clear. CONCLUSION: The survey adds to the limited body of evidence in this clinical area and can be a useful tool for health economists in determining the additional cost of treating patients with drug-resistant infections.
Authors: Nicole M White; Adrian G Barnett; Lisa Hall; Brett G Mitchell; Alison Farrington; Kate Halton; David L Paterson; Thomas V Riley; Anne Gardner; Katie Page; Christian A Gericke; Nicholas Graves Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079
Authors: Louisa G Gordon; Thomas M Elliott; Brian Forde; Brett Mitchell; Philip L Russo; David L Paterson; Patrick N A Harris Journal: BMJ Open Date: 2021-02-01 Impact factor: 2.692